| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vascular Biology |
From the Department of Clinical and Experimental Medicine (G.C., A.G., I.P., E.I., E.P., G.P.F., M.A., A.S., A.A.), Chemical Sciences (L.F.), University of Padova Medical School, Italy.
Correspondence to Prof Angelo Avogaro, Department of Clinical and Experimental Medicine, University of Padova, Via Giustiniani 2 35128 Padova, Italy. E-mail angelo.avogaro{at}unipd.it
Objective— Hyperglycemia is the main determinant of long-term diabetic complications, mainly through induction of oxidative stress. NAD(P)H oxidase is a major source of glucose-induced oxidative stress. In this study, we tested the hypothesis that rosiglitazone (RSG) is able to quench oxidative stress initiated by high glucose through prevention of NAD(P)H oxidase activation.
Methods and Results— Intracellular ROS were measured using the fluoroprobe TEMPO-9-AC in HUVECs exposed to control (5 mmol/L) and moderately high (10 mmol/L) glucose concentrations. NAD(P)H oxidase and AMPK activities were determined by Western blot. We found that 10 mmol/L glucose increased significantly ROS production in comparison with 5 mmol/L glucose, and that this effect was completely abolished by RSG. Interestingly, inhibition of AMPK, but not PPAR
, prevented this effect of RSG. AMPK phosphorylation by RSG was necessary for its ability to hamper NAD(P)H oxidase activation, which was indispensable for glucose-induced oxidative stress. Downstream of AMPK activation, RSG exerts antioxidative effects by inhibiting PKC.
Conclusions— This study demonstrates that RSG activates AMPK which, in turn, prevents hyperactivity of NAD(P)H oxidase induced by high glucose, possibly through PKC inhibition. Therefore, RSG protects endothelial cells against glucose-induced oxidative stress with an AMPK-dependent and a PPAR
-independent mechanism.
The present study was designed to characterize the molecular mechanisms underlying the effects of rosiglitazone on hyperglycemia-induced ROS production in HUVECs. We demonstrate that rosiglitazone reduces glucose-induced oxidative stress through inhibition of NAD(P)H oxidase. This effect is not mediated by PPAR
but is dependent on AMPK activation and downstream PKC inhibition.
Key Words: diabetes AMPK NAD(P)H oxidase oxidative stress rosiglitazone
This article has been cited by other articles:
![]() |
H.-C. Yang, S. Deleuze, Y. Zuo, S. A. Potthoff, L.-J. Ma, and A. B. Fogo The PPAR{gamma} Agonist Pioglitazone Ameliorates Aging-Related Progressive Renal Injury J. Am. Soc. Nephrol., November 1, 2009; 20(11): 2380 - 2388. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-N. Li, J. Song, L. Zhang, S. A. LeMaire, X. Hou, C. Zhang, J. S. Coselli, L. Chen, X. L. Wang, Y. Zhang, et al. Activation of the AMPK-FOXO3 Pathway Reduces Fatty Acid-Induced Increase in Intracellular Reactive Oxygen Species by Upregulating Thioredoxin Diabetes, October 1, 2009; 58(10): 2246 - 2257. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Xu and M.-H. Zou Molecular Insights and Therapeutic Targets for Diabetic Endothelial Dysfunction Circulation, September 29, 2009; 120(13): 1266 - 1286. [Full Text] [PDF] |
||||
![]() |
M. A. Potenza, S. Gagliardi, L. De Benedictis, A. Zigrino, E. Tiravanti, G. Colantuono, A. Federici, L. Lorusso, V. Benagiano, M. J. Quon, et al. Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature Am J Physiol Endocrinol Metab, September 1, 2009; 297(3): E685 - E694. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Oak, C. Tran, M.-O. Castillo, S. Thamotharan, M. Thamotharan, and S. U. Devaskar Peroxisome proliferator-activated receptor-{gamma} agonist improves skeletal muscle insulin signaling in the pregestational intrauterine growth-restricted rat offspring Am J Physiol Endocrinol Metab, August 1, 2009; 297(2): E514 - E524. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Fisslthaler and I. Fleming Activation and Signaling by the AMP-Activated Protein Kinase in Endothelial Cells Circ. Res., July 17, 2009; 105(2): 114 - 127. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang, Y. Huang, K. S.L. Lam, Y. Li, W. T. Wong, H. Ye, C.-W. Lau, P. M. Vanhoutte, and A. Xu Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase Cardiovasc Res, June 1, 2009; 82(3): 484 - 492. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. W. Jeong, K. C. Hsu, J.-W. Lee, M. Ham, J. Y. Huh, H. J. Shin, W. S. Kim, and J. B. Kim Berberine suppresses proinflammatory responses through AMPK activation in macrophages Am J Physiol Endocrinol Metab, April 1, 2009; 296(4): E955 - E964. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |